Karyopharm Therapeutics | KPTI - Betriebsergebnis

Aktienkurs
8.28
Täglich Wechseln
0.28 3.50%
Monatlich
-3.16%
Jährlich
96.67%
Q2 Prognose
7.78




Betriebsergebnis Veränderung Datum
AbbVie USD 5.81B 1.23B 2025-12
Abbott USD 2.25B 73M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Incyte USD 383.88M 47.43M 2025-12
J&J USD 5.59B 1.81B 2025-12
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD 6.24B 318M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.06B 437M 2025-12
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Takeda JPY 168.82B 479.89B 2025-12
Tectonic Therapeutic USD -21.52M 374K 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Xencor USD -53.63M 6.11M 2025-12